M&A Deal Summary

Horizon Therapeutics Acquires OPKO Health - Sterile Fill & Finish Manufacturing Facility

On June 17, 2021, Horizon Therapeutics acquired life science company OPKO Health - Sterile Fill & Finish Manufacturing Facility from Opko for 65M USD

Acquisition Highlights
  • This is Horizon Therapeutics’ 11th transaction in the Life Science sector.
  • This is Horizon Therapeutics’ 7th largest (disclosed) transaction.
  • This is Horizon Therapeutics’ 1st transaction in Ireland.

M&A Deal Summary

Date 2021-06-17
Target OPKO Health - Sterile Fill & Finish Manufacturing Facility
Sector Life Science
Buyer(s) Horizon Therapeutics
Sellers(s) Opko
Deal Type Divestiture
Deal Value 65M USD

Target

OPKO Health - Sterile Fill & Finish Manufacturing Facility

Waterford, Ireland
OPKO Health - Sterile Fill & Finish Manufacturing Facility engages in the development and commercial supply of high potency, high barrier to entry, pharmaceutical products for sale.

Search 195,137 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Horizon Therapeutics

Dublin, Ireland

website


Category Company
Founded 2005
Sector Life Science
Employees2,100
Revenue 3.2B USD (2021)
DESCRIPTION

Horizon Therapeutics is a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. The Company markets seven medicines through its orphan, primary care and specialty business units. Horizon Therapeutics was founded in 2005 and is based in Dublin, Ireland.


DEAL STATS #
Overall 11 of 11
Sector (Life Science) 11 of 11
Type (Divestiture) 4 of 4
Country (Ireland) 1 of 1
Year (2021) 2 of 2
Size (of disclosed) 7 of 10
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2021-02-01 Viela Bio

Gaithersburg, Maryland, United States

Viela Bio is dedicated to the development and commercialization of novel, life-changing medicines for patients with a wide range of autoimmune and severe inflammatory diseases. Viela Bio was founded in 2018 and is based in Gaithersburg, United States.

Buy $3.1B

Seller(S) 1

SELLER

Opko

Miami, Florida, United States

website


Category Company
Founded 1991
Sector Life Science
Employees5,269
Revenue 1.0B USD (2022)
DESCRIPTION
Opko's corporate headquarters in Miami, Florida.
Opko's corporate headquarters in Miami, Florida.

Opko is a diversified healthcare company that seeks to establish industry-leading positions in large and rapidly growing medical markets. Opko's diagnostics business includes Bio-Reference Laboratories, a clinical laboratory with a core genetic testing business and a 420-person salesforce to drive growth and leverage new products, including the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. Opko's pharmaceutical business includes Rayaldee, a treatment for secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease and vitamin D insufficiency and VARUBI for chemotherapy-induced nausea and vomiting. Opko's pharmaceutical business also includes OPKO Biologics, which features hGH-CTP, a once-weekly human growth hormone injection and a longer acting Factor VIIa drug for hemophilia. Opko was founded in 1991 and is based in Miami, Florida.


DEAL STATS #
Overall 3 of 3
Sector (Life Science) 2 of 2
Type (Divestiture) 3 of 3
Country (Ireland) 1 of 1
Year (2021) 1 of 1
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2017-02-17 CareEvolve

Elmwood Park, New Jersey, United States

CareEvolve is a provider of internet based order entry and results reporting solutions for laboratory, pathology and radiology outreach businesses.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2022-05-09 ModeX Therapeutics

Natick, Massachusetts, United States

ModeX Therapeutics has developed highly flexible multi-specific antibody technology platforms with broad targeting and functional capabilities, simpler manufacturing, and potentially better specificity and safety, providing significant differentiation from competing platforms. ModeX Therapeutics was founded in October 2020 with headquarters in Natick, Massachusetts.

Buy $300M